MA5-13141

antibody from Invitrogen Antibodies

Targeting: MS4A1 B1, Bp35, CD20, MS4A2

Provider product page for MA5-13141

Western blot

Antibody data

Antibody Data
Antigen structure
References [65]
Comments [0]
Validations
Western blot [2]
Immunocytochemistry [1]
Immunohistochemistry [1]
Flow cytometry [3]
Other assay [4]

Submit

Product number: MA5-13141 - Provider product page
Provider: Invitrogen Antibodies
Product name: CD20 Monoclonal Antibody (L26)
Antibody type: Monoclonal
Antigen: Other
Description: This product is recommended for qualitative immunohistochemistry with normal and neoplastic formalin-fixed, paraffin-embedded tissues, to be viewed by light microscopy. Staining requires boiling tissue in 10mM citrate buffer, pH 6.0, for 10-20 min followed by cooling at room temperature for 20 min. This antibody will not cross-react with cow, dog, pig or rat.
Antibody clone number: L26
Concentration: Conc. Not Determined

MS4A1 protein structure - MA5-13141 shown in red.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Flow cytometry analysis of CD20 in BAF-3 cells compared to an isotype control (blue). Cells were harvested, adjusted to a concentration of 1-5x10^6 cells/ml, fixed with 2% paraformaldehyde and washed with PBS. Cells were blocked with a 2% solution of BSA-PBS for 30 min at room temperature and incubated with a CD20 monoclonal antibody (Product # MA5-13141) at a dilution of 1:2 for 60 min at room temperature. Cells were then incubated for 40 min at room temperature in the dark using a Dylight 488-conjugated goat anti-mouse IgG (H+L) secondary antibody and re-suspended in PBS for FACS analysis.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Flow cytometry analysis of CD20 in Raji cells compared to an isotype control (blue). Cells were harvested, adjusted to a concentration of 1-5x10^6 cells/mL, fixed with 2% paraformaldehyde and washed with PBS. Cells were blocked with a 2% solution of BSA-PBS for 30 min at room temperature and incubated with a CD20 monoclonal antibody (Product # MA5-13141) at a dilution of 1:2 for 60 min at room temperature. Cells were then incubated for 40 min at room temperature in the dark using a Dylight 488-conjugated goat anti-mouse IgG (H+L) secondary antibody and re-suspended in PBS for FACS analysis.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Flow cytometry analysis of CD20 in Ramos cells compared to an isotype control (blue). Cells were harvested, adjusted to a concentration of 1-5x10^6 cells/mL, fixed with 2% paraformaldehyde and washed with PBS. Cells were blocked with a 2% solution of BSA-PBS for 30 min at room temperature and incubated with a CD20 monoclonal antibody (Product # MA5-13141) at a dilution of 1:2 for 60 min at room temperature. Cells were then incubated for 40 min at room temperature in the dark using a Dylight 488-conjugated goat anti-mouse IgG (H+L) secondary antibody and re-suspended in PBS for FACS analysis.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 6 Identification of immune cell populations in the tumour microenvironment. ( a ) Immune cell clusters were characterized by gene ontology terms. The cluster-specific genes extracted by LRT test (left) were associated with B cells, T cells or macrophages (MO), respectively (right). ( b ) Immunofluorescence staining (IF) for CD3 or CD20 showing the infiltration of T or B lymphocytes in tumour tissues. Scale bar, 20 mum. ( c ) Immunofluorescence staining results show significant correlations with gene expression in bulk tumour samples (Pearson's r , 0.66 for CD3 and 0.67 for CD20, P

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 1 Presence of CD3 + T cells and CD20 + B cells in postmortem preterm infant brains with periventricular leukomalacia (PVL). (A-C) CD3 + T cell immunohistochemical staining in the periventricular white matter (A,C) and meninges (B) of brain sections from postmortem preterm infant brains with (case 4) and without (case 1) PVL. (D-F) CD20 + B cell immunohistochemical staining in the periventricular white matter (D,F) and meninges (E) of brain sections from postmortem preterm infant brains with (case 5) and without (case 3) PVL. Positively stained cells are indicated by arrowheads. The inserts show a higher magnification of positively stained cells.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 2 High-dimensional flow cytometry and immunohistochemistry reveal distinct TIL-B phenotypes and increased tertiary lymphoid structures in HPV+ HNSCC. a viSNE plots of B cells collected from non-inflamed and inflamed tonsils, HPV+ and HPV- HNSCC TIL and paired PBL (Supplementary Fig. 7 ) were analyzed using Cytobank. Non-inflamed tonsil ( n = 4), inflamed tonsil ( n = 6), HPV + HNSCC ( n = 3), HPV- HNSCC ( n = 2). Bar plot displaying frequencies of GC B cells and plasma cells in non-inflamed tonsil ( n = 9), inflamed tonsil ( n = 16), HPV+ HNSCC ( n = 9), HPV- HNSCC ( n = 9). * P = 0.02 Student's 2-sided t test. b Bar plot for frequency of B cell subpopulations. Non-inflamed tonsil ( n = 9), inflamed tonsil ( n = 16), HPV+ HNSCC ( n = 12), HPV- HNSCC ( n = 13). ** P = 0.004, *** P = 0.0009, * P = 0.03, One way ANOVA followed by Tukey's multiple comparisons test. c Frequencies of T follicular helper (T FH ), regulatory T follicular helper (T FHreg ), regulatory T cell (T reg ), T helper type 1 (T H 1) and CD8 T cells in non-inflamed tonsil ( n = 6), inflamed tonsils ( n = 10), HPV+ TIL ( n = 7), HPV- TIL ( n = 8). * P = 0.01,** P = 0.009,**** P < 0.0001. * P = 0.04, * P = 0.03, **** P < 0.0001. One-way ANOVA followed by Tukey's multiple comparisons test. d Representative CD20+ IHC on HPV+ and HPV- HNSCC tumors (x4 magnification). e B cell infiltrate counted within tumor bed compared to TLS. Total numbers from n = 50, 25 HPV+, 25 HPV- were graphed. **** P < 0.0001, Student'

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 6 Increased TLS with GC within HPV+ HNSCC patients correlate with increased patient survival. a Annotated tumor section stained for CD20 via single-plex IHC from a HNSCC patient (x20 magnification). Annotations for tumor (intratumoral and peritumoral) and non-tumor areas are indicated. Blue circle =TLS without GC, Pink circle = TLS with GC, Purple square = TIL-B infiltrate within tumor bed. b Representative Vectra staining for TLS with GC within HPV+ and HPV- HNSCC tumors. BOT = base of tongue. c TLS with GC are increased intratumorally (intra) and peritumorally (peri) in HPV+ HNSCC patients. Differences in intra vs. peri TLS with GC trended toward an increase in HPV+ HNSCC patients. Data are presented as mean values +- SEM. d TLS with GC in the tumors of HPV+ and HPV- HNSCC patients correlate with increased patient survival. Cox proportional hazard was used to evaluate overall survival based on high versus low frequencies of TLS with GC and HPV status ( p = 0.003, log rank test). The hazard ratio for high versus low TLS with GC was 0.32, and the hazard ratio for HPV+ versus HPV- was 0.27. e Total number of tumor TLS are increased in HPV+ patients that do not progress to secondary disease. Total tumor TLS (via CD20 + staining) were compared by primary disease (1deg) vs. primary and secondary disease (1deg+2deg). n = 50, 25 HPV+, 25 HPV-. * P = 0.0336 and 0.0281, Student's 2 sided t test. Data are presented as mean values +- SEM. f Total number of tumor TLS are increased